Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

Phase 1 Completed 5 enrolled Prolong Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End Stage Renal Disease (ESRD).

Timeline

Start: 2015-06-05
Primary completion: 2015-11-18
Completion: 2015-11-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	pegylated carboxyhemoglobin bovine	Protein / enzyme biologic	—	—

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

Summary

Timeline

Drugs

Indications